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Abstract
Background
To evaluate the predictive value of carotid atherosclerotic disease (CAD) and intima-media
thickness (IMT) on incident cardiovascular disease and mortality in hemodialysis patients.
Methods
Multicenter, observational, prospective study including 110 patients, followed-up to 6 years.
Carotid doppler ultrasonographic findings were classified in 4 degrees of severity: 1) IMT
<0.9 mm, 2) IMT >0.9 mm, 3) carotid plaque with stenosis <50% and 4) plaque with stenosis
>50%. The associations between IMT and CAD and cardiovascular events, total and car-
diovascular mortality were assessed.
Results
83% of the patients had atherosclerotic plaques (CAD degrees 3-4). During follow-up, 29.1%
of patients experienced cardiovascular events, and 28.2% died, 38.7% of cardiovascular ori-
gin. The presence of plaques was associated with cardiovascular events (p = 0.03) while cal-
cified plaques were associated with both cardiovascular events (p = 0.01), cardiovascular
mortality (p = 0.03) and non-significantly with overall mortality (p = 0.08) in the survival analy-
sis. Carotid IMT was not associated with outcomes. Cardiovascular events correlated with
CAD severity (HR 2.27, 95% CI 1.13-4.54), age (HR 1.04, 1.01-1.06), previous cardiovascu-
lar disease (HR 1.75, 1.05-4.42), dyslipidemia (HR 2.25, 1.11-4.53), lipoprotein (a) (HR 1.01,
1.00-1.02), troponin I (HR 3.89, 1.07-14.18), fibrinogen levels (HR 1.38, 0.98-1.94) and anti-
platelet therapy (HR 2.14, 1.04-4.4). In an age-adjusted multivariate model, cardiovascular
events were independently associated with previous coronary artery disease (HR 3.29,
1.52-7.15) and lipoprotein (a) (HR 1.01, 1.00-1.02).
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Conclusions
The presence of carotid plaques and, especially, calcified plaques, are predictors of new
cardiovascular events and cardiovascular mortality in hemodialysis patients, while IMT was
not. The prognostic value of calcified plaques should be confirmed in future studies.
Introduction
Cardiovascular (CV) disease is the main cause of mortality in hemodialysis (HD) patients [1–
4]. However, the high prevalence of CV disease and traditional CV risk factors, such as hyper-
tension, diabetes, smoking, dyslipidemia, sedentary lifestyle, or left ventricular hypertrophy, do
not fully explain this increased CV risk in uremic patients [5,6]. In fact, the Framingham Risk
Score underestimates the CV risk in HD patients, thus suggesting that other factors are in-
volved in the development and progression of the CV disease in these patients [5]. In recent
years, several markers have been reported to have prognostic implications in dialysis patients
[7]. Among them, an increased carotid intima-media thickness (IMT) has been associated with
CV disease and risk of stroke, both in the general population and in HD patients [8,9]. This pa-
rameter is associated with traditional and emerging CV risk factors, as well as with the progres-
sion, stabilization, and regression of atherosclerosis with lipid-lowering and antihypertensive
treatments in the general population [10–13].
On the other hand, the presence of carotid plaques is considered as target organ damage by
the ESH-ESC Practice Guidelines for the Management of Hypertension, and it is an indepen-
dent marker of increased risk and the likelihood of CV events or mortality in HD patients
[9,14,15]. It is tempting to speculate that, while IMT may be a better marker of arteriosclerosis
and arterial stiffness, which are highly prevalent in HD patients, carotid atherosclerosis (pres-
ence of plaques) is a marker of subclinical atherosclerosis and a better predictor of CV events
than IMT in these patients.
Currently, the assessment of IMT and carotid plaques is not uniform, making it difficult to
interpret and compare the results between studies [16]. In addition, there are only few long–
term prospective studies evaluating the prognostic value of carotid ultrasound findings in the
HD population [9,15,17,18].
The aim of this study was to assess the predictive value of carotid IMT, the presence of ca-
rotid atherosclerotic plaques and their characteristics, on the incidence of CV disease and over-
all and CV mortality in HD patients.
Material and Methods
Design
This was a multicenter, observational, cross-sectional and prospective study including 110
adult patients with end-stage renal disease on maintenance HD for at least 6 months from the
Hospital Clinic and 4 satellite HD units. Patients had to be clinically stable and without evi-
dence of clinical heart failure at the time of enrollment. Clinical heart failure was defined as
dyspnea plus two of the following conditions: increased jugular venous pressure, bibasilar pul-
monary rales, pulmonary venous hypertension or interstitial edema requiring hospitalization
or ultrafiltration and/or a left ventricular ejection fraction<25%. Patients agreed to participate
in the study and signed an informed written consent. The study was approved by the Ethics’
Committee of the Hospital Clinic (Barcelona, Spain).
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All patients underwent a carotid Doppler ultrasound study, evaluating the common carotid,
bifurcation and the origin of the internal carotid artery, analyzing the presence of plaques, calci-
fications and degree of stenosis (1–4) [16], in addition to measuring the carotid IMT according
to the Mannheim Consensus 2006. Carotid atherosclerotic disease (CAD) was classified in 4 de-
grees of severity (Grade 1: IMT<0.9 mm, grade 2: IMT> 0.9 mm, grade 3: presence of carotid
plaques with stenosis<50% and grade 4: presence of carotid plaques with stenosis>50%).
At baseline, anthropometric, demographic, clinical and analytical data were collected at
baseline: age, sex, time on HD, previous kidney transplants, and etiology of renal disease; histo-
ry of CV risk factors (hypertension, diabetes, hypercholesterolemia, smoking); characteristics
of the HD, and concomitant treatments (antihypertensive, lipid-lowering and antiplatelet/anti-
coagulant agents, vitamin D analogs, erythropoiesis stimulating agents and doses of calcium
and intravenous iron). The Charlson comorbidity index was also calculated. Patients were fol-
lowed up for a maximum of 6 years, and events including: CV disease of cardiac origin (defined
as coronary artery disease events, congestive heart failure or cardiac arrhythmias), cerebrovas-
cular events (stroke or transient ischemic attack) and peripheral arterial events (peripheral ar-
tery disease, mesenteric ischemia, etc.), as well as total and CV mortality were collected, until
death, loss to follow-up or kidney transplantation. The associations of CAD and IMT with CV
events, CV and overall mortality were prospectively assessed.
Methods
Blood pressure was measured before each HD session during one week. Blood samples were
obtained before the second dialysis session of the week after 20–30 minutes of rest in a supine
position. At baseline, the following biochemical and hematological parameters were also mea-
sured: calcium, phosphorus, CaxP product, iPTH, total cholesterol, LDL-cholesterol, triglycer-
ides, hemoglobin, fibrinogen, ferritin, C reactive protein (CRP), blood urea nitrogen (BUN)
and Kt/V. Additional special tests included: lipoprotein (a), homocysteine, troponin-I and
brain natriuretic peptide (BNP).
Carotid Doppler ultrasound was performed with the model color Doppler ultrasound
equipment and software to measure IMT. We used a high resolution linear transducer with 7.5
MHz of frequency and 0.1 mm of resolution in real time image and 3.75 MHz for Doppler.
Subjects were placed in a supine position with the head rotated 45°, contralateral to the exam-
ined carotid. Three segments were examined: the common carotid artery at 1 cm proximal to
the carotid bulb, the carotid bifurcation (1–2 cm) and the origin of the internal carotid (1 cm
distal to the bifurcation) bilaterally. Carotid IMT was measured at 1 cm prebifurcation, ex-
plored in a longitudinal section on the far wall, obtaining 4 measurements at regular intervals.
We calculated the average of 8 measurements, right and left, considering as a normal value an
IMT 0.9 mm, according to the criteria of the European Guidelines on Hypertension of the
ESC-ESH of 2007 [14]. We defined the presence of plaque as a focal structure that invaded the
arterial lumen of at least 0.5 mm or>50% of the surrounding IMT or demonstrated a thicken-
ing>1.5 mmmeasured from the media-adventitia interface to the intima-lumen interface
[16]. For plaque evaluation, longitudinal and transverse section in B mode were performed and
then, analyzed in each vessel by color Doppler and describing the location, number and struc-
tural ultrasonographic features, including calcification.
Statistical analysis
Data were analyzed using the software Statistical Package for the Social Sciences (SPSS, version
20.0, SPSS Inc). Comparison of continuous variables was performed by using the Student's t
test for unpaired data and the Chi-square test for qualitative variables. If continuous variables
Carotid Atherosclerosis and Cardiovascular Risk in Hemodialysis
PLOS ONE | DOI:10.1371/journal.pone.0127344 June 1, 2015 3 / 12
did not show a normal distribution, data were analyzed using the Mann-Whitney´s U test. Sur-
vival analysis was carried out by using the Kaplan-Meier test and multivariate Cox regression
analysis. A P-value<0.05 was considered significant.
Results
Demographics and baseline assessment
The demographic parameters of the 110 patients included are summarized in Table 1. Sixty
nine percent were male, mean age was 58.9 ± 15.3 years and median time on HD 37 [14.75,
85.5] months. The mean Charlson comorbidity index was 5.26 ± 2.18 points, and 27.3% of the
patients had had a previous renal transplant. The most common causes of end-stage renal dis-
ease were vascular (19.1%) and glomerular (19.1%), followed by unknown etiology (16.4%)
and diabetic nephropathy (15.5%). The prevalence of CV disease at baseline was 52.7%: 46.4%
of patients had a history of cardiac disease and 17.3% had non-cardiac vascular disease
Table 1. Descriptive analysis of the hemodialysis population and carotid ultrasound findings.
(Mean ± SD)(Cases/%)
Patients (n) 110
Age (years) 58.9 ± 15.3
Sex (male/female) 76 (69.1%)/34 (30.9%)
Charlson Comorbidity Index 5.26 ± 2.18
Body mass index (Kg/m2) 24.33 ± 4.39
Time on HD (months) 37 [14.75, 85.5]
Dialysis dose (eKt/V) 1.35 ± 0.22
Previous kidney transplant 30 (27.3%)
Previous heart disease 51 (46.4%)
Previous cerebrovascular or peripheral artery disease 19 (17.3%)
Mean blood pressure (mmHg) 90.72 ± 13.18
Tobacco use (yes/no/former) 23/63/24 (20.9%/57.3%/21.8%)
Diabetes mellitus (yes/no) 24 (21.8%)/86 (78.2%)
Hypertension (yes/no) 94 (85.5%)/16 (14.5%)
Dyslipidemia (yes/no) 43 (39.1%)/67 (60.9%)
Left ventricular hypertrophy (yes/no) 34 (30.9%)/76 (69.1%)
IMT mean (mm) 0.78 ± 0.28 mm
IMT > 0.9 mm 37 (40.2%)
Presence of Plaques 93 (83.6%)
Calciﬁed plaques 80 (72.7%)
Presence of Stenosis 43 (39.1%)
< 50% 32 (29.1%)
50–70% 8 (7.3%)
> 70% 2 (1.8%)
Occlusion 1 (0.9%)
Stage classiﬁcation according to IMT and plaques
Grade 1 (IMT <0.9 mm, no plaques) 17 (15.5%)
Grade 2 (IMT >0,9 mm, no plaques) 1 (0.9%)
Grade 3 (Plaque with stenosis <50%) 81 (73.6%)
Grade 4 (Plaque with stenosis >50%) 11 (10%)
HD: Hemodialysis. IMT: Intima media thickness.
doi:10.1371/journal.pone.0127344.t001
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(cerebrovascular disease or peripheral artery disease). The prevalence of traditional CV risk
factors is included in Table 1.
Mean IMT was 0.78 ± 0.28 mm (n = 92). In 40.2% of the cases, IMT was abnormal. The
presence of carotid plaques was very common (83.6% of patients), showing some degree of ste-
nosis in 43 of them (39.1%). Furthermore, most patients had their plaques calcified (72%).
Thus, most of our patients were allocated to the more severe degrees of our CAD classification
(degrees 3–4) (Table 1 and S1 Fig).
In the univariate analysis, pathological carotid IMT was positively associated with age, male
sex, previous CV disease, smoking, Charlson comorbidity index and pulse pressure. And nega-
tively with history of a previous transplant, serum phosphate levels and calcium-phosphorus
product (Table 2).
The presence of atherosclerotic plaques showed a positive correlation with age, hyperten-
sion, history of arrhythmia, IMT, Charlson comorbidity index, pulse pressure, left ventricular
mass index, CRP and fibrinogen levels. We did not find differences with daily calcium dose
or calcium/phosphorous product between patients with calcified plaques and non-calcified
plaques.
Prospective observational study
During a mean follow-up of 3.17 ± 2.07 years, 42 (38.2%) patients received a kidney transplant
and 11 patients (10%) were lost to follow-up. Thirty-two patients (29.1%) suffered new cardiac
(69%) or vascular events (31%), the most frequent type being coronary artery disease-related
events, such as acute myocardial infarction (22%); arrhythmia (19%), heart failure (16%) and
Table 2. Association between abnormal intima-media thickness (IMT) and plaques with clinical and laboratory parameters.
IMT >0.9 mm
(n = 37)
IMT <0.9 mm
(n = 55)
P-Value (IMT>0,9
vs <0,9)
Plaques
(n = 92)
No plaques
(n = 18)
P-Value (plaques vs
no plaques)
Sex (M/F) 31/6 32/23 0.01 64/28 12/6 0.78
Age (years) 66.3 ± 12.7 52.7 ± 14.1 <0.001 61.7 ± 14.3 44.7 ± 12.3 <0.001
Time on HD (months) 38 [15, 86] 57 [20,144] 0.33 37 [17,84] 39 [11,174] 0.87
Charlson comorbidity index 6.16 ± 2.15 4.4 ± 1.89 <0.001 5.5 ± 2.17 4.06 ± 1.86 0.01
Previous kidney transplant
(yes/no)
6/31 21/34 0.03 24/68 6/12 0.56
Tobacco (yes/no) 21/16 16/39 0.01 42/50 5/13 0.19
Hypertension (yes/no) 33/4 46/9 0.55 84/8 10/8 0.001
Calcium (mg/dl) 9.31 ± 0.85 9.05 ± 1.0 0.19 9.28 ± 0.94 8.8 ± 0.77 0.07
Phosphate (mg/dl) 5.09 ± 1.28 6.04 ± 1.76 0.006 5.71 ± 1.72 5.76 ± 1.82 0.9
Calcium Phosphorus product 47.2 ± 11.9 54.4 ± 15.7 0.01 52.7 ± 15.7 51.3 ± 17.8 0.73
Pulse pressure (mmHg) 63.8 ± 18 54.6 ± 17.1 0.02 59.9 ± 16.7 50.0 ± 14.4 0.03
Arrhythmia (yes/no) 13/24 5/50 0.003 22/70 0/18 0.02
Prevalent cardiovascular
disease (yes/no)
13/24 35/20 0.01 41/51 12/6 0.12
Cardiovascular events (yes/
no)
12/25 12/43 0.33 31/61 1/17 0.02
Intima media thickness (mm) 0.81 ± 0.28 0.58 ± 0.14 0.04
Left ventricular mass (g) 252.5 ± 57.8 273.1 ± 56.4 0.12 273.5 ± 64.9 228.7 ± 49.1 0.01
CRP (mg/dl) 1.05 ± 1.31 1.08 ± 0.95 0.9 1.17 ± 1.2 0.56 ± 0.59 0.003
Fibrinogen (g/l) 4.42 ± 0.97 4.65 ± 0.81 0.25 4.73 ± 0.88 3.8 ± 0.78 <0.001
HD: Hemodialysis. CRP: C reactive protein
doi:10.1371/journal.pone.0127344.t002
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peripheral vascular disease (16%). Total mortality was 28.2%, being of CV origin in 38.7% of
cases. Among the CV causes of death the most frequent were also myocardial infarction (13%),
sudden death (10%) and vascular pathology (9%). Among the non-CV causes of mortality, the
most frequent were infectious diseases (26%), followed by bleeding (16%), and cancer (10%)
(S1 Table). Patients with previous cardiovascular disease had more new cardiovascular events
(36.2%, 21/58) and a higher total mortality (32.75%, 19/58) during the follow-up compared
with patients without prevalent cardiovascular disease at baseline (21.15%, 11/52 and 23% 12/
52, respectively).
In the Kaplan Meier survival analysis, the most severe degrees of carotid atherosclerotic dis-
ease (degrees 3 and 4) were associated with new CV events (p = 0.03) (Fig 1). Overall and CV
Fig 1. Actuarial survival in patients according to carotid atherosclerotic disease grades (grade 1–2
versus grade 3–4) and calcified versus non-calcified plaques. A) Survival analysis of patients free of
cardiovascular events. B) Cardiovascular mortality-free patients. C) Overall mortality free patients.
doi:10.1371/journal.pone.0127344.g001
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mortality were also higher in the group with severe CAD, but without reaching statistical
significance.
The presence of calcified plaques was associated with new CV events (p = 0.01), CVmortality
(p = 0.03) and non-significantly with overall mortality in the survival analysis (p = 0.08) (Fig 1).
Carotid IMT did not correlate with new CV events, overall or CV mortality in our analysis.
Cox regression analysis and multivariate analysis
In the univariate Cox regression analysis, new cardiovascular events showed a positive correla-
tion with CAD severity (HR 2.27, 95% CI 1.13–4.54, p = 0.02), age (HR 1.04, 95% CI 1.01–1.06,
p = 0.004), previous CV disease (HR 1.75, 95% CI 1.05–4.42, p = 0.03) and, especially, coronary
artery disease (HR 4.14, 95% CI 2.05–8.37, p<0.001), as well as, dyslipidemia (HR 2.25, 95% CI
1.11–4.53, p = 0.02), lipoprotein (a) (HR 1.01, 95% CI 1.00–1.02, p = 0.02), troponin I (HR
3.89, 95% CI 1.07–14.18, p = 0.03), antiplatelet therapy (HR 2.14, 95% CI 1.04–4.4, p = 0.03)
and fibrinogen levels (HR 1.38, 95% CI 0.98–1.94, p = 0.05) (Table 3). And negatively with dia-
stolic blood pressure (HR 0.97, 95% CI 0.95–1.00, p = 0.05). All these significant values were in-
cluded in a stepwise multivariate Cox model. In the final multivariate model, new CV events
were independently associated with age (HR: 1.04, 95% CI 1.01–1.06, p = 0.007), history of cor-
onary artery disease (HR: 3.29, 95% CI 1.52–7.15, (p = 0.003) and lipoprotein (a) (HR: 1.01,
95% CI 1.00–1.02, p = 0.02) (Table 3).
Discussion
The main results of our study are the high prevalence of carotid atherosclerosis and the pre-
dominance of calcified plaques in hemodialysis patients. The presence of carotid plaques, rath-
er than IMT, predicted new cardiovascular events during the follow-up. Furthermore, the
presence of calcified plaques predicted both new cardiovascular events, as well as CV mortality,
thus suggesting the additional predictive value of plaque calcification in hemodialysis patients.
The presence of carotid plaques has been reported to be present in more than 60% of hemo-
dialysis patients in several studies [9,19–21]. An increased plaque burden and a higher preva-
lence of plaque calcification has been reported in this population vs the general population
[21,22]. In hemodialysis patients, authors have found association with different types of carotid
atherosclerosis and CV risk: such as the sum of the thickness of all plaques found [21], with the
sum of bilateral location of all plaques [22], while others propose scores based on the number
or calcification of plaques [19].
Ultrasonographic and necropsic studies have shown a much higher prevalence of calcified
plaques in ESRD patients than in age-matched controls, in whom soft plaques are more fre-
quent [20,23]. Although it has been suggested that calcified plaques are more stable; this con-
cept has been recently challenged in ESRD by some studies that have shown that the
atherosclerotic plaques of CKD patients are more complex than those of individuals with nor-
mal renal function. Coronary plaques in patients with CKD had a larger lipid core with a
higher content of calcium, cholesterol crystals and plaque disruption, as well as intraplaque
hemorrhage and new intimal vessels, compared with non-CKD patients [24,25], suggesting
that atherosclerotic plaques in CKD patients are more vulnerable, despite the higher presence
of calcium.
ESRD is associated with an increased IMT, as well as arteriosclerosis, vascular calcification,
and subsequent arterial stiffness [9,26–28]. Although carotid IMT has been traditionally consid-
ered a marker of subclinical atherosclerosis in the general population [29] and in dialysis patients
[30], recent studies indicate that the addition of this parameter to traditional cardiovascular risk
factor prediction models does not significantly improve their performance in the general
Carotid Atherosclerosis and Cardiovascular Risk in Hemodialysis
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population [10]. Carotid IMT has been found to be associated with the presence of prevalent CV
disease, traditional cardiovascular risk factors (age, male gender, smoking, diabetes, dyslipide-
mia, hypertension), as well as malnutrition-inflammation status and different biomarkers in he-
modialysis patients [9,26,28]. In our study, IMT was associated with age, male sex, prevalent CV
disease, smoking, but not with other cardiovascular risk factors or markers of malnutrition-in-
flammation. Carotid IMT was also associated with pulse pressure, which can be considered a
surrogate of arterial stiffness; but did not predict new cardiovascular events or mortality in our
patients. Although some studies have shown a relationship between IMT and mortality in hemo-
dialysis [9,31], this relationship may be indirect, since IMT was associated with prevalent cardio-
vascular disease and the presence of plaques. Thus, in our hands, IMT seems to be a marker of
arteriosclerosis, rather than atherosclerosis and CV risk in these patients.
The association of carotid atherosclerosis with cardiovascular events and/or mortality has
been previously reported in dialysis patients [19,32]. Benedetto et al [15] further found that the
rate of formation of new plaques was a strong, independent predictor of incident cardiovascu-
lar events in ESRD, while changes in IMT did not predict cardiovascular outcomes. Several
studies in dialysis patients [9,19] and in the general population [10,33] have shown that the
presence of plaques is a better prognostic marker than IMT. Our results are in agreement with
these previous studies, further supporting that the presence of carotid atherosclerosis is a better
predictor of future CV events than IMT.
Furthermore, in our study the presence of calcified plaques was also associated with both
fatal and non-fatal cardiovascular events. Our results show the prognostic value of calcified pla-
ques as a cardiovascular risk marker, similarly to previous studies [19,32], and its association
Table 3. Univariate and Multivariate Cox regression analyses for cardiovascular events in hemodialysis patients.
Univariate analysis Multivariate analysis
Variable HR (CI 95%) P-Value HR (CI 95%) P-Value
Age (years) 1.04 (1.01–1.06) 0.004 1.04 (1.01–1.06) 0.007
CAD (yes/no) 2.27 (1.13–4.54) 0.02
Previous cardiovascular disease (yes/no) 1.75 (1.05–4.42) 0.03
Previous coronary heart disease (yes/no) 4.14 (2.05–8.37) <0.001 3.29 (1.52–7.15) 0.003
Dyslipidemia (yes/no) 2.25 (1.11–4.53) 0.02
Diabetes Mellitus (yes/no) 0.91 (0.39–2.12) 0.84
Hypertension (yes/no) 2.11 (0.64–6.95) 0.22
Tobacco (yes/no) 1.19 (0.59–2.38) 0.62
SBP (mmHg) 0.99 (0.98–1.01) 0.54
DBP (mmHg) 0.97 (0.95–1.00) 0.05
PP (mmHg) 1.00 (0.98–1.02) 0.62
Total cholesterol (mg/dl) 0.99 (0.98–1.01) 0.54
LDL-c (mg/dl) 1.00 (0.98–1.01) 0.87
Lipoprotein (a) (mg/dl) 1.01 (1.00–1.02) 0.02 1.01 (1.00–1.02) 0.02
CRP (mg/dl) 1.21 (0.95–1.54) 0.11
Troponin I (ng/ml) 3.89 (1.07–14.18) 0.03
Fibrinogen (g/l) 1.38 (0.98–1.94) 0.05
Antiplatelet therapy (yes/no) 2.14 (1.04–4.40) 0.03
ACE inhibitors / ARB treatment (yes/no) 0.15 (0.02–1.11) 0.06
CAD: carotid atherosclerosis disease, SBP: systolic blood pressure, DBP: diastolic blood pressure, PP: pulse pressure, CRP: C reactive protein, ACE:
angiotensin converting enzyme, ARB: Angiotensin receptor blockers
doi:10.1371/journal.pone.0127344.t003
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with cardiovascular morbidity and mortality in dialysis patients. However, the additional pre-
dictive value of plaque composition on the cardiovascular risk in this population deserves
further research.
Carotid plaque calcification has been associated to secondary hyperparathyroidism [34],
hypoalbuminaemia and the chronic inflammatory state, although other studies failed to find
these relationships, neither with age nor with time on dialysis [20]. In our study, in agreement
with Savage et al [20] we failed to find a relationship between the presence of calcified plaques
with markers of bone mineral metabolism, such as levels of phosphorus, calcium or iPTH; pre-
scribed daily dose of calcium or vitamin D administration, although this issue remains contro-
versial [34].
Lipid abnormalities and serum lipoprotein (a) levels are associated with IMT, the presence
and number plaques, suggesting a role for lipoprotein (a) as an independent risk factor for ath-
erosclerosis in this population [35,17]. We found no relationship between lipid abnormalities
or Lp (a) and IMT, in contrast to other studies (22), Lp (a) levels were associated with the sever-
ity of CAD in the univariate analysis, and with the incidence of cardiovascular events in the
multivariate analysis, in agreement with previous studies [36]. Our results also found an associ-
ation between CAD severity and serum troponin-I levels, suggesting its association with sub-
clinical myocardial injury.
We recognize the limitations of the present study. The definition of high-risk CAD was
based on published data linking severity and plaque characteristics. Although we had an ade-
quate long-term monitoring with minimal losses, the number of patients studied was limited,
as well as the incidence of some types of CV events, especially stroke. In addition, we did not
conduct additional carotid US examinations during the follow-up or considered time-averaged
levels of clinical and analytical parameters, thus our analyses relied on baseline measurements,
limiting the validity of our results, considering the high variability of some serum parameters
and the evolution of carotid atherosclerosis. The association between carotid atherosclerosis
and calcified plaques with the incidence of cardiovascular events was lost in the multivariate
analysis, which may be due to the low sample size and number of events. Thus, further studies
with higher sample sizes and more events should confirm our findings. The evolution of pa-
tients that received a kidney transplant after the transplant was unknown since we discontin-
ued the follow-up.
Conclusions
In summary, we found that the echographic severity of CAD, and, especially, the presence of
calcified plaques, are predictors of CV events, while IMT was not, in prevalent hemodialysis
patients. These results challenges the general believe that calcified plaques are more stable, at
least in this population. Larger prospective studies are needed to assess the relevance of CAD
and, specifically, calcified CAD, as CV outcome predictors in ESRD patients. Carotid ultra-
sound is a simple and non-invasive tool that can help to evaluate the atherosclerotic burden in
uremic patients and, perhaps, in combination with other imaging or biochemical markers may
improve the CV risk prediction in this population. This is especially relevant in our hemodialy-
sis patients in whom the Framingham risk score underestimates their actual cardiovascular
risk [5].
Supporting Information
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